SHELTON, CT / ACCESSWIRE / May 10, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum…
Heavily pre-treated breast cancer patient who achieved stable disease on study, remains on treatment for more than eleven months after…
Heavily pre-treated breast cancer patient who achieved stable disease on study, remains on treatment for more than eleven months after…
NV-387 Possesses Strong Orthopoxvirus Activity Relevant to Both Sexual and Inhalation Modes of Transmission, Says NanoViricides SHELTON, CT / ACCESSWIRE…
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc.…
NV-387 Possesses Strong Anti-Influenza-A Virus Activity, and May Have Activity Against H5N1 Bird Flu Virus, Says NanoViricides SHELTON, CT /…
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June…
SHELTON, CT / ACCESSWIRE / April 30, 2024 / NanoViricides, Inc. (NYSE Amer:NNVC) (the "Company"), a global leader in broad-spectrum…
Antibody rise observed in lactating mothers and in their breast milk Long-term goal is to provide protection to infants through…
BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea), a clinical-stage biopharmaceutical company engaged in the…